Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OGEN by emailGet an email when OGEN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OGEN, unsubscribe in one click. Privacy
📣 What OGEN Says Is Next
Q4 2026 · “A Phase IIa feasibility trial is currently enrolling at three sites in Australia, and the Company is advancing its Investigational New Drug (IND) application, with submission anticipated in Q4 2026.”
Company press release, Sep 16, 2026 · SEC filing
by the end of 2026 · “Second, we are targeting submission of the full Investigational New Drug application by the end of 2026, which would position Oragenics to initiate U.S.-based clinical trials in 2027.”
Company press release, May 19, 2026 · SEC filing
Q4 2026 · “Oragenics expects that findings will support its planned investigational new drug (IND) application submission to the FDA, targeting Q4 2026, for the next phase of clinical trials to be conducted in the U.S. Clinical Foundation & Operational Partners The Phase 1 clinical trial of ONP-002 delivered a strong safety profile, with zero serious adverse events reported across all dose levels in 40 patients, supporting advancement to Phase 2.”
Company press release, Apr 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OGEN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OGEN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.